http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108752316-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725
filingDate 2018-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-108752316-B
titleOfInvention Tetrahydroisoquinoline-2-methylbenzimidazole salt compound and preparation method and application thereof
abstract The invention provides a tetrahydroisoquinoline-2-methylbenzimidazole salt compound, belonging to the field of organic compounds. The invention designs and synthesizes a series of tetrahydroisoquinoline-2-methylbenzimidazole salt compounds based on two pharmacophores of tetrahydroisoquinoline and 2-methylbenzimidazole so as to research the biological activity of the compounds, thereby discovering new molecules with good anti-tumor activity and providing material basis and new guiding significance for further medicinal chemical research. The experimental data of the embodiment show that the tetrahydroisoquinoline-2-methylbenzimidazole salt compounds with the structure shown in the formula I have obvious in-vitro tumor growth inhibition activity on 5 human cancer cells (leukemia, liver cancer, lung cancer, breast cancer and colon cancer cells), and the in-vitro tumor growth inhibition activity of part of the compounds on A-549, MCF-7 and SW480 is superior to that of an anticancer drug cisplatin (DDP).
priorityDate 2018-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453034310
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11984
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12998085
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415729613
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414869730
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537701
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426183542
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61147
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425322823
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407074167
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516892
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70320
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11789594
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6228
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420230429
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7046
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID69179
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415741883
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559095
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6344
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425386533
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441203
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15885183

Total number of triples: 41.